查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1422809

2024-2032 年按技術、治療領域、最終用戶和地區分類的人類絨毛膜促性腺激素市場報告

Human Chorionic Gonadotropin Market Report by Technology, Therapeutic Area, End User, and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 139 Pages | 商品交期: 2-3個工作天內

價格

2023年，全球人絨毛膜促性腺激素（HCG）市場規模達到9.735億美元。展望未來， IMARC Group預計到2032年市場規模將達到17.684億美元，2024-2032年復合年成長率（CAGR）為6.65 %。女性不孕症發病率的上升、性腺機能減退相關疾病盛行率的增加以及使用重組技術生產 HCG 是推動市場發展的一些關鍵因素。

人類絨毛膜促性腺激素（HCG）是懷孕期間胎盤合體滋養層細胞產生的化學物質。它存在於血液、尿液、肝臟、結腸和腦下垂體。 HCG 刺激黃體產生黃體酮以維持懷孕。它是透過離子交換層析、染料親和色譜、奈米濾和反相高效液相層析 (HPLC) 等多種技術從孕婦的尿液中提取和純化用於臨床應用。 HCG 廣泛用於治療不孕症、增加懷孕機會、幫助睪固酮和精子的產生以及治療男孩隱睪症。它還有助於診斷和監測與妊娠相關的疾病、產前篩檢和婦科癌症。

人類絨毛膜促性腺激素 (HCG) 市場趨勢：

由於子宮疾病、輸卵管阻塞、多囊性卵巢症候群（PCOS）和內分泌系統疾病導致的女性不孕症發生率上升是推動市場成長的關鍵因素之一。 HCG廣泛應用於各種輔助生殖技術，如體外受精（IVF）和子宮內人工授精（IUI），以治療女性不孕症，因為它有助於誘導排卵，促進胚胎形成，促進卵母細胞的正確時機檢索，增加子宮內膜厚度，提高子宮內膜容受性。除此之外，與其他生育藥物結合使用以增加女性懷孕機會的廣泛產品也是另一個生長誘導因素。此外，由於患有肥胖和第2型糖尿病的男性性腺機能減退相關疾病的盛行率不斷增加，HCG擴大應用於提高睪固酮水平、增強生育能力和促進性功能，這有利於市場的成長。此外，與天然來源的 HCG 相比，使用重組技術生產的 HCG 具有相同的特性、增強的功效和更高的安全性，並增強患者的耐受性，這對市場成長產生了積極影響。其他因素，包括醫療保健基礎設施的快速發展、不孕症治療和服務的不斷增加、老年人口的增加、為推出新型純化和提取技術而進行的廣泛研究和開發（R＆D）活動，以及實施各種政府措施改善人們的性健康，預計將進一步推動市場成長。

本報告回答的關鍵問題：

  • 迄今為止，全球人類絨毛膜促性腺激素（HCG）市場表現如何，未來幾年將如何表現？
  • 全球人類絨毛膜促性腺激素 (HCG) 市場的促進因素、限制因素和機會是什麼？
  • 主要區域市場有哪些？
  • 哪些國家代表了最具吸引力的人類絨毛膜促性腺激素 (HCG) 市場？
  • 基於技術的市場區隔是什麼？
  • 基於治療領域的市場區隔是什麼？
  • 基於最終用戶的市場區隔是什麼？
  • 全球人類絨毛膜促性腺激素（HCG）市場的競爭結構如何？
  • 全球人類絨毛膜促性腺激素 (HCG) 市場的主要參與者/公司有哪些？

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

  • 概述
  • 主要行業趨勢

第 5 章：全球人類絨毛膜促性腺激素 (HCG) 市場

  • 市場概況
  • 市場業績
  • COVID-19 的影響
  • 市場預測

第 6 章：市場區隔：依技術

  • 天然來源萃取
    • 市場走向
    • 市場預測
  • 重組技術
    • 市場走向
    • 市場預測

第 7 章：市場區隔：依治療領域

  • 女性不孕症治療
    • 市場走向
    • 市場預測
  • 男性性腺功能減退症
    • 市場走向
    • 市場預測
  • 少精治療
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 8 章：市場區隔：依最終用戶

  • 生育診所
    • 市場走向
    • 市場預測
  • 研究機構
    • 市場走向
    • 市場預測
  • 其他
    • 市場走向
    • 市場預測

第 9 章：市場區隔：按地區

  • 北美洲
    • 美國
      • 市場走向
      • 市場預測
    • 加拿大
      • 市場走向
      • 市場預測
  • 亞太
    • 中國
      • 市場走向
      • 市場預測
    • 日本
      • 市場走向
      • 市場預測
    • 印度
      • 市場走向
      • 市場預測
    • 韓國
      • 市場走向
      • 市場預測
    • 澳洲
      • 市場走向
      • 市場預測
    • 印尼
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 歐洲
    • 德國
      • 市場走向
      • 市場預測
    • 法國
      • 市場走向
      • 市場預測
    • 英國
      • 市場走向
      • 市場預測
    • 義大利
      • 市場走向
      • 市場預測
    • 西班牙
      • 市場走向
      • 市場預測
    • 俄羅斯
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 拉丁美洲
    • 巴西
      • 市場走向
      • 市場預測
    • 墨西哥
      • 市場走向
      • 市場預測
    • 其他
      • 市場走向
      • 市場預測
  • 中東和非洲
    • 市場走向
    • 市場細分：按國家/地區
    • 市場預測

第 10 章：促進因素、限制與機會

  • 概述
  • 促進要素
  • 限制
  • 機會

第 11 章：價值鏈分析

第 12 章：波特五力分析

  • 概述
  • 買家的議價能力
  • 供應商的議價能力
  • 競爭程度
  • 新進入者的威脅
  • 替代品的威脅

第 13 章：價格分析

第14章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • Biocare Medical LLC
    • Ferring Pharmaceuticals
    • Fresenius SE & Co. KGaA
    • Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
    • Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
    • Merck & Co. Inc.
    • Prospec-Tany Technogene Ltd.
    • Scripps Laboratories Inc.
    • Sun Pharmaceutical Industries Limited
Product Code: SR112024A7059

Abstract

The global human chorionic gonadotropin (HCG) market size reached US$ 973.5 Million in 2023. Looking forward, IMARC Group expects the market to reach US$ 1,768.4 Million by 2032, exhibiting a growth rate (CAGR) of 6.65% during 2024-2032. The rising incidences of infertility in women, increasing prevalence of hypogonadism-related disorders, and production of HCG using recombinant technology represent some of the key factors driving the market.

Human chorionic gonadotropin (HCG) is a chemical produced by syncytiotrophoblastic cells of the placenta during pregnancy. It is found in blood, urine, liver, colon, and pituitary glands. HCG stimulates the corpus luteum to produce progesterone to maintain the pregnancy. It is extracted and purified from the urine of pregnant women for clinical applications using various techniques, such as ion exchange chromatography, dye-affinity chromatography, nanofiltration, and reverse-phase high-performance liquid chromatography (HPLC). HCG is widely used to treat infertility, increase the chances of pregnancy, help in the production of testosterone and sperm, and treat cryptorchidism in male children. It also aids in diagnosing and monitoring pregnancy-related disorders, prenatal screening, and gynecological cancers.

Human Chorionic Gonadotropin (HCG) Market Trends:

The rising incidences of infertility among females due to uterine disorders, blocked fallopian tube, polycystic ovarian syndrome (PCOS), and endocrine system disorders are among the key factors driving the market growth. HCG is widely used in various assisted reproductive technologies, such as in-vitro fertilization (IVF) and intrauterine insemination (IUI), to treat female infertility, as it aids in inducing ovulation, promotes the formation of the embryo, facilitates correct timing of oocyte retrieval, increases endometrial thickness, and improve endometrial receptivity. In addition to this, the widespread product utilization in combination with other fertility drugs to increase the chances of pregnancy in women is acting as another growth-inducing factor. Furthermore, the increasing application of HCG to improve testosterone levels, enhance fertility, and promote sexual function due to the increasing prevalence of hypogonadism-related disorders in males suffering from obesity and type 2 diabetes is favoring the market growth. Additionally, the production of HCG using recombinant technology that provides identical properties, enhanced efficacy, and improved safety compared to naturally sourced HCG and enhances patient tolerance is positively influencing the market growth. Other factors, including the rapid development of healthcare infrastructure, increasing availability of treatment and services regarding infertility, rising geriatric population, extensive research and development (R&D) activities for the launch of novel purification and extraction technologies, and the implementation of various government initiatives to improve the sexual health of people, are anticipated to drive the market growth further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global human chorionic gonadotropin (HCG) market, along with forecasts at the global, regional, and country level from 2024-2032. Our report has categorized the market based on technology, therapeutic area, and end user.

Technology Insights:

Natural Source Extraction

Recombinant Technology

The report has also provided a detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the technology. This includes natural source extraction and recombinant technology. According to the report, natural source extraction represented the largest segment.

Therapeutic Area Insights:

Female Infertility Treatment

Male Hypogonadism

Oligospermic Treatment

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the therapeutic area has been provided in the report. This includes female infertility treatment, male hypogonadism, oligospermic treatment, and others. According to the report, female infertility treatment accounted for the largest market share.

End User Insights:

Fertility Clinics

Research Institutions

Others

A detailed breakup and analysis of the human chorionic gonadotropin (HCG) market based on the end user has been provided in the report. This includes fertility clinics, research institutions, and others. According to the report, fertility clinics accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets that include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and Middle East and Africa. According to the report, North America was the largest market for human chorionic gonadotropin (HCG). Some of the factors driving the North America human chorionic gonadotropin (HCG) market include rising incidences of infertility among women, growing consumer awareness regarding the available treatment for infertility and gynecological concerns, and rising expenditure capacities of consumers.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global human chorionic gonadotropin (HCG) market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Biocare Medical LLC, Ferring Pharmaceuticals, Fresenius SE & Co. KGaA, Kamiya Biomedical Company (Nitto Boseki Co. Ltd.), Lee Biosolutions Inc. (Oy Medix Biochemica Ab), Merck & Co. Inc., Prospec-Tany Technogene Ltd., Scripps Laboratories Inc., Sun Pharmaceutical Industries Limited, etc.

Key Questions Answered in This Report:

  • How has the global human chorionic gonadotropin (HCG) market performed so far and how will it perform in the coming years?
  • What are the drivers, restraints, and opportunities in the global human chorionic gonadotropin (HCG) market?
  • What are the key regional markets?
  • Which countries represent the most attractive human chorionic gonadotropin (HCG) markets?
  • What is the breakup of the market based on the technology?
  • What is the breakup of the market based on the therapeutic area?
  • What is the breakup of the market based on the end user?
  • What is the competitive structure of the global human chorionic gonadotropin (HCG) market?
  • Who are the key players/companies in the global human chorionic gonadotropin (HCG) market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Human Chorionic Gonadotropin (HCG) Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Technology

  • 6.1 Natural Source Extraction
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Recombinant Technology
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Therapeutic Area

  • 7.1 Female Infertility Treatment
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Male Hypogonadism
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Oligospermic Treatment
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Fertility Clinics
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Research Institutions
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 Drivers, Restraints, and Opportunities

  • 10.1 Overview
  • 10.2 Drivers
  • 10.3 Restraints
  • 10.4 Opportunities

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocare Medical LLC
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Ferring Pharmaceuticals
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 Fresenius SE & Co. KGaA
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 Kamiya Biomedical Company (Nitto Boseki Co. Ltd.)
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Lee Biosolutions Inc. (Oy Medix Biochemica Ab)
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Prospec-Tany Technogene Ltd.
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 Scripps Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Sun Pharmaceutical Industries Limited
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Human Chorionic Gonadotropin Market: Major Drivers and Challenges
  • Figure 2: Global: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018-2023
  • Figure 3: Global: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 4: Global: Human Chorionic Gonadotropin Market: Breakup by Technology (in %), 2023
  • Figure 5: Global: Human Chorionic Gonadotropin Market: Breakup by Therapeutic Area (in %), 2023
  • Figure 6: Global: Human Chorionic Gonadotropin Market: Breakup by End User (in %), 2023
  • Figure 7: Global: Human Chorionic Gonadotropin Market: Breakup by Region (in %), 2023
  • Figure 8: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 9: Global: Human Chorionic Gonadotropin (Natural Source Extraction) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 10: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 11: Global: Human Chorionic Gonadotropin (Recombinant Technology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 12: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 13: Global: Human Chorionic Gonadotropin (Female Infertility Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 14: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 15: Global: Human Chorionic Gonadotropin (Male Hypogonadism) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 16: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 17: Global: Human Chorionic Gonadotropin (Oligospermic Treatment) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 18: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 19: Global: Human Chorionic Gonadotropin (Other Therapeutic Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 20: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 21: Global: Human Chorionic Gonadotropin (Fertility Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 22: Global: Human Chorionic Gonadotropin (Research Institutions) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 23: Global: Human Chorionic Gonadotropin (Research Institutions) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 24: Global: Human Chorionic Gonadotropin (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 25: Global: Human Chorionic Gonadotropin (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 26: North America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 27: North America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 28: United States: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 29: United States: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 30: Canada: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 31: Canada: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 32: Asia-Pacific: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 33: Asia-Pacific: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 34: China: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 35: China: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 36: Japan: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 37: Japan: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 38: India: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 39: India: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 40: South Korea: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 41: South Korea: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 42: Australia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 43: Australia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 44: Indonesia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 45: Indonesia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 46: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 47: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 48: Europe: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 49: Europe: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 50: Germany: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 51: Germany: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 52: France: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 53: France: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 54: United Kingdom: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 55: United Kingdom: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 56: Italy: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 57: Italy: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 58: Spain: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 59: Spain: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 60: Russia: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 61: Russia: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 62: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 63: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 64: Latin America: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 65: Latin America: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 66: Brazil: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 67: Brazil: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 68: Mexico: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 69: Mexico: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 70: Others: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 71: Others: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 72: Middle East and Africa: Human Chorionic Gonadotropin Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 73: Middle East and Africa: Human Chorionic Gonadotropin Market: Breakup by Country (in %), 2023
  • Figure 74: Middle East and Africa: Human Chorionic Gonadotropin Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Global: Human Chorionic Gonadotropin Industry: Drivers, Restraints, and Opportunities
  • Figure 76: Global: Human Chorionic Gonadotropin Industry: Value Chain Analysis
  • Figure 77: Global: Human Chorionic Gonadotropin Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Human Chorionic Gonadotropin Market: Key Industry Highlights, 2023 & 2032
  • Table 2: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Technology (in Million US$), 2024-2032
  • Table 3: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Therapeutic Area (in Million US$), 2024-2032
  • Table 4: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 5: Global: Human Chorionic Gonadotropin Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 6: Global: Human Chorionic Gonadotropin Market: Competitive Structure
  • Table 7: Global: Human Chorionic Gonadotropin Market: Key Players